what tier are glp 1 drugs Mapping the effectiveness and risks of GLP-1 receptor agonists Clinical Focus on GLP-1 Agonists

Obesity Disease Burden and Population Health ROI Framework Economic Cost of Obesity, Comorbidity Cascade, and GLP-1 Pharmacotherapy Value-Based Evidence Reshape Global Treatment Investment The Global Obesity Forum estimated total annual economic costs of obesity at USD 4.32 trillion annually in 2025 , representing 2.92% of global GDP and exceeding the full economic output of Germany

20 TECOS (2015) did not show an increased risk of HF in patients taking sitagliptin for treatment of type 2 diabetes

By 2024, an estimated 12% of American adults reported taking a GLP-1 medication for diabetes, weight loss, or heart disease, according to data from the Kaiser Family Foundation

However, she called the osteoporosis finding an early signal, noting that I dont think its conclusive. Future research on GLP-1 medications should focus on the incidence of fractures, which bone density loss can increase risk of, she said

Interventions that support mitochondrial efficiency, stabilize nutrient sensing, and limit the accumulation of senescent cells may contribute to preserving physiological resilience, even if they do not directly alter the primary drivers of aging